AbCellera Biologics Inc (NASDAQ:ABCL) traded at $3.36 at last check on current trade day and made an upward move of 7.35% on its previous day’s price.
Looking at the stock we see that its previous close was $3.13 and the beta (5Y monthly) reads 0.351 with the day’s price range being $3.15 – $3.38. In terms of its 52-week price range, ABCL has a high of $6.05 and a low of $2.34. The company’s stock has gained about 15.86% over that past 30 days.
AbCellera Biologics Inc has a market cap of $1.03 billion and is expected to release its quarterly earnings report in February.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 7.58M, with a low of 4.35M and a high of 11.74M. The median projection represents growth adding up to -17.62% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 31.58M, or -16.95% down from figures reported last year.
On the other hand, looking at the outlook for the ABCL stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy.
Based on estimates by 9 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the AbCellera Biologics Inc (ABCL) stock as a Hold, while 7 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 14.48% off its SMA20 and 17.24% from its 50-day simple moving average. The RSI (14) is pointing at 66.83 while the volatility over the past week is 5.96% and jumps to 5.97% over the past one month. The beta value is 0.40, while the average true range (ATR) is currently pointing at 0.18. The average price target for the stock over the next 12 months is $5, with the estimates having a low of $5 and a high of $5. These price ends are -48.81% and -48.81% off the today’s price level respectively, although investors could be excited at the prospect of a -48.81% if the ABCL share price touches on the median price of $5.
Coming back to AbCellera Biologics Inc (NASDAQ:ABCL), we note that the average 3-month trading volume was 2.39 million, while that of the preceding 10-day period stands at 2.49 million. Current shares outstanding are 295.16 million.
The insiders hold 24.86% of the company’s shares while institutions hold 34.60%. The data shows that short shares as of 2024-12-13, stood at 15.89 million at a short ratio of 6.42. This represents a 698.00 short interest in shares outstanding on 2024-12-13. Shares short fall in December from the previous month at 15.93 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock 14.68% up in year-to-date price movement.
